List of Excipients in Branded Drug GALLIUM CITRATE GA-67

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Curium US LLC	GALLIUM CITRATE GA-67	gallium citrate ga-67	69945-180	BENZYL ALCOHOL
Curium US LLC	GALLIUM CITRATE GA-67	gallium citrate ga-67	69945-180	HYDROCHLORIC ACID
Curium US LLC	GALLIUM CITRATE GA-67	gallium citrate ga-67	69945-180	SODIUM CHLORIDE
Curium US LLC	GALLIUM CITRATE GA-67	gallium citrate ga-67	69945-180	SODIUM HYDROXIDE
Curium US LLC	GALLIUM CITRATE GA-67	gallium citrate ga-67	69945-180	TRISODIUM CITRATE DIHYDRATE

Gallium Citrate Ga-67 Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Gallium citrate Ga-67 is an established diagnostic radiopharmaceutical with limited formulation complexity and little apparent value in conventional excipient innovation. Its commercial opportunity is concentrated in reliable isotope supply, radiochemical quality, hospital and nuclear-pharmacy distribution, manufacturing efficiency, and applications in infection and inflammation imaging. The product is not a biologic, does not create biosimilar exposure, and has no meaningful composition-of-matter patent barrier comparable with newer oncology drugs.

What is gallium citrate Ga-67 and how is it used?

Gallium citrate Ga-67 is a radioactive diagnostic agent containing gallium-67, generally supplied as a sterile injectable solution of gallium-67 in a citrate medium. Gallium-67 has a physical half-life of approximately 78 hours and emits gamma radiation suitable for planar imaging and SPECT acquisition.

The product has historically been used to image:

• Hodgkin lymphoma and selected other malignancies
• Inflammatory disease
• Osteomyelitis and other bone infections
• Pulmonary and systemic infections
• Fever of unknown origin
• Opportunistic infections in immunocompromised patients

Its clinical use has declined because fluorodeoxyglucose F-18 PET/CT, labeled leukocyte imaging, FDG-based oncology imaging, and newer infection-imaging approaches provide faster or more specific alternatives in many indications. Gallium citrate Ga-67 remains relevant where PET access is limited, where prolonged inflammatory localization is useful, or where nuclear medicine departments maintain established Ga-67 protocols.

The product is usually administered intravenously. Imaging commonly occurs at delayed intervals because gallium distribution and lesion uptake evolve over time. That delay affects scheduling, inventory management, patient throughput, and the commercial value of local radiopharmacy production.

What excipients are used in gallium citrate Ga-67 injection?

Gallium citrate Ga-67 formulations generally use a citrate-containing aqueous vehicle. Public labeling for gallium citrate Ga-67 injection identifies the formulation as a sterile solution containing gallium-67 associated with citrate and may include benzyl alcohol as a preservative, depending on the product and presentation. Product-specific labeling controls the exact excipient composition, concentration, pH range, preservative status, and storage conditions. (U.S. Food and Drug Administration [FDA], n.d.-a)

Core excipient functions

Formulation component	Technical role	Commercial importance
Sodium citrate or citrate species	Complexes gallium and controls solution chemistry	High
Water for injection	Injectable vehicle	High
Benzyl alcohol, where present	Preservative in selected multidose presentations	Moderate
pH adjustment agents	Maintains formulation stability and injectability	Moderate
Container-closure system	Protects sterility and limits adsorption or contamination	High

Citrate is the principal formulation variable. Gallium chemistry is sensitive to pH, hydrolysis, precipitation, and competing ligands. The citrate concentration must support a reproducible gallium species without creating excessive free citrate, altered biodistribution, or injection-site tolerability concerns.

A commercial formulation should avoid unnecessary excipients. Every additional component adds extractables and leachables, sterility, compatibility, labeling, and quality-control requirements. The preferred strategy is a simple, low-volume, citrate-buffered aqueous injection with validated radiochemical purity and a container system suitable for radioactive materials.

How should an excipient strategy be designed for Ga-67?

The most defensible strategy is to optimize the existing citrate platform rather than pursue a novel excipient system.

1. Control gallium speciation

The formulation should maintain gallium in a reproducible citrate-associated state during shelf life and through administration. Development work should evaluate:

• Citrate concentration
• pH
• Ionic strength
• Gallium concentration
• Radiolytic degradation
• Free gallium and hydrolyzed gallium species
• Precipitation under refrigerated and room-temperature conditions

Radiochemical purity is more commercially important than a differentiated excipient claim. A formulation that improves the percentage of usable, correctly complexed Ga-67 can reduce failed batches, repeat imaging, and nuclear-pharmacy waste.

2. Minimize radiolysis

Ga-67 is radioactive for several days, creating an extended window for radiolytic effects compared with short-lived PET products. The formulation and packaging should be assessed for:

• Radiolytic breakdown of citrate
• pH drift
• Formation of colloidal gallium
• Particulate generation
• Changes in appearance
• Loss of radiochemical purity
• Interaction with elastomeric closures

Antioxidants could be evaluated, but they should not be added automatically. An antioxidant may alter gallium coordination, create new impurities, complicate toxicology, or provide no meaningful stability gain. A citrate-only formulation can be commercially preferable if it meets stability and release specifications.

3. Select single-dose or multidose packaging carefully

Single-dose vials reduce preservative exposure and simplify sterility claims. Multidose presentations can improve nuclear-pharmacy economics but may require preservatives, validated repeated puncture performance, and tighter microbial-control procedures.

Benzyl alcohol is commercially useful where a multidose product is needed, but its inclusion creates labeling considerations for neonates, infants, and vulnerable populations. A preservative-free single-dose vial may have a stronger hospital-positioning profile even if it carries a higher per-dose packaging cost.

4. Match the container to the radiopharmacy workflow

A Ga-67 product may be stored, transported, assayed, and dispensed across several days. Container-closure development should address:

• Radiation shielding
• Vial adsorption
• Stopper compatibility
• Dose withdrawal accuracy
• Residual volume
• Label readability after shielding
• Transport vibration and temperature excursions
• Sterility through the labeled use period

The optimal package may be a low-residual-volume vial with a standardized shield and a presentation compatible with automated dose calibrator workflows.

What patents protect gallium citrate Ga-67?

Gallium citrate Ga-67 is an old diagnostic radiopharmaceutical, and its core active ingredient and citrate formulation are unlikely to be protected by enforceable modern composition-of-matter patents. The commercial position is primarily based on manufacturing controls, regulatory approval, isotope access, distribution, and quality systems.

Protection category	Relevance to gallium citrate Ga-67
Composition-of-matter patent	Little apparent commercial relevance
Basic citrate formulation patent	Likely expired or difficult to enforce as a broad claim
Method-of-use patent	Limited value because historical diagnostic uses are established
Orange Book patent listing	No material patent-based exclusivity is generally associated with the legacy product
Regulatory exclusivity	Historic product-specific exclusivity would not be the principal current barrier
Manufacturing know-how	Potentially important
Isotope supply and logistics	Potentially decisive
Trademark and product rights	Relevant to market access and contracting

A new patent estate could target a specific technical improvement, such as improved radiochemical stability, a defined citrate concentration range, a low-radiolysis formulation, a specialized container, or an automated compounding process. Broad claims covering gallium citrate in water would face substantial prior-art and obviousness risks.

Can excipient patents create defensible protection?

Yes, but the strongest claim strategy would require measurable technical advantages. Potential claim themes include:

• A defined citrate-to-gallium ratio that reduces colloidal gallium
• A preservative-free formulation with extended radiochemical stability
• A container-closure combination that limits adsorption or radiolysis
• A formulation stable through a specified activity range
• A kit for dose preparation and quality control
• A production method that improves yield or reduces radioactive waste

A patent directed only to the use of citrate as a buffer or complexing agent would likely have limited strength unless it captures a narrow, unexpected performance result.

When does gallium citrate Ga-67 lose exclusivity?

Gallium citrate Ga-67 does not have a practical, upcoming loss-of-exclusivity event comparable with a branded small-molecule medicine. The underlying drug technology has been commercially available for decades. Any historic patents covering early gallium radiopharmaceutical formulations or uses would generally be expected to have expired.

The relevant commercial question is therefore not patent expiry. It is whether a manufacturer can obtain or maintain an approved product, secure Ga-67 supply, meet sterile injectable requirements, and deliver doses to nuclear medicine sites within the usable activity window.

What is the FDA regulatory status of gallium citrate Ga-67?

Gallium citrate Ga-67 injection is an FDA-regulated diagnostic radiopharmaceutical. The product is administered under the applicable drug and radiopharmaceutical framework, with requirements covering:

• Identity and assay of gallium-67
• Radionuclidic purity
• Radiochemical purity
• Sterility
• Bacterial endotoxins
• Particulate matter
• pH
• Container closure
• Expiration dating
• Radiation-safety labeling

FDA labeling has historically identified gallium citrate Ga-67 as an injectable diagnostic agent. Current commercial availability can vary because radiopharmaceutical products are affected by isotope supply, production-site status, nuclear-pharmacy demand, and manufacturing interruptions. The FDA Drug Shortages database and Drugs@FDA provide the relevant regulatory and supply-status records. (FDA, n.d.-b; FDA, n.d.-c)

What is the Orange Book status of gallium citrate Ga-67?

The Orange Book is less commercially informative for this product than it is for a conventional branded oral drug. Gallium citrate Ga-67 is a legacy injectable diagnostic product with no widely recognized active patent or regulatory-exclusivity strategy driving generic entry.

Potential entrants would generally compete through an abbreviated or alternative approval pathway appropriate to the product and its reference listing, subject to FDA requirements. The key barriers are product equivalence, sterile manufacturing, radiochemical performance, isotope availability, and distribution rather than Paragraph IV patent litigation.

Are there Paragraph IV challenges or biosimilar risks?

No conventional biosimilar risk exists because gallium citrate Ga-67 is a radioactive small-molecule diagnostic drug, not a biologic.

Paragraph IV litigation is also unlikely to be the central entry mechanism. A prospective entrant would have limited economic incentive to challenge an expired legacy formulation patent. If a new manufacturer obtains patents on a modernized formulation, container, or manufacturing process, those claims could create a Paragraph IV issue, but the scope would likely be narrow and technically specific.

The more probable competitive pattern is parallel entry by approved radiopharmaceutical manufacturers, nuclear pharmacies, hospital-based facilities, and regional suppliers.

What manufacturing and intellectual-property barriers exist?

Isotope supply

Ga-67 is produced through cyclotron-based or reactor-related routes depending on the manufacturing network and supply chain. The isotope has a relatively long half-life compared with many PET radionuclides, but it still requires controlled production, transport, assay, and release.

Sterile manufacturing

A manufacturer needs validated aseptic processing, radiation-protection controls, environmental monitoring, qualified personnel, and release testing. Small batch sizes can increase unit costs.

Quality-control testing

Testing may include gamma spectrometry, radiochemical purity analysis, radionuclidic identity, sterility, endotoxins, pH, visual inspection, and particulate assessment. A robust quality system can be a stronger barrier than a patent.

Distribution

The product must reach hospitals while retaining sufficient activity for scheduled imaging. Regional manufacturing and dose-calibrator integration can create an advantage over centralized supply.

What commercial opportunities exist for gallium citrate Ga-67?

The largest opportunities are operational and geographic.

Opportunity	Commercial rationale
Reliable regional supply	Reduces cancellations caused by shortages or transport delays
Preservative-free single-dose vials	Supports hospital safety and simplified administration
Improved stability	Extends usable inventory and reduces waste
Nuclear-pharmacy contract supply	Provides recurring institutional demand
Emerging-market access	PET availability is uneven across regions
Infection and inflammation imaging	Preserves selected non-oncology demand
Kit-based radiopharmacy workflow	Reduces preparation variability
Hospital reserve inventory	Supports urgent imaging and shortage mitigation

A manufacturer can also compete on service metrics: delivery reliability, activity calibration, product availability on specific imaging days, technical support, and waste reduction. These attributes may influence purchasing more than a marginal excipient change.

How does gallium citrate Ga-67 compare with competing imaging agents?

Product	Main strength	Main limitation	Competitive effect on Ga-67
Gallium citrate Ga-67	Established infection and tumor imaging; longer usable activity window	Delayed imaging; lower specificity in some settings	Legacy and niche demand
F-18 FDG PET/CT	High oncology adoption; broad availability in PET networks	Requires PET infrastructure; short half-life	Major substitution pressure
Indium-111-labeled leukocytes	Useful for selected infection indications	Complex labeling and delayed imaging	Indication-specific competitor
Technetium-99m agents	Broad nuclear medicine infrastructure	Different biological targeting	Partial competitive overlap
Gallium-68 targeted agents	Modern PET performance and disease-specific targeting	Requires generator or cyclotron supply and newer infrastructure	Increasing pressure in specialized indications

Ga-67 is most commercially defensible where PET capacity is limited, infection imaging protocols are established, or a hospital values a longer logistical window than short-lived PET products provide.

What litigation and settlement risks affect the product?

Patent litigation, settlement agreements, and Paragraph IV disputes are not expected to be the principal commercial risks for a legacy Ga-67 citrate product. The main legal exposures are more likely to involve:

• Manufacturing defects
• Sterility failures
• Dose-assay discrepancies
• Product shortages
• Distribution contracts
• Radiation-safety compliance
• Labeling and promotional claims
• Facility licensing and nuclear-material controls

A new formulation patent could change that profile, but a commercially meaningful dispute would likely center on a narrow formulation or manufacturing claim rather than the gallium citrate active ingredient itself.

Key Takeaways

• Gallium citrate Ga-67 is a legacy diagnostic radiopharmaceutical with limited formulation complexity.
• Citrate control, radiochemical purity, radiolysis management, and container compatibility are the central technical issues.
• A simple preservative-free single-dose formulation may provide the clearest commercial positioning.
• Patent-based exclusivity is not the principal barrier; isotope supply, sterile manufacturing, quality systems, and distribution are more important.
• No biosimilar risk exists, and Paragraph IV litigation is unlikely to drive the market.
• Commercial opportunities are strongest in reliable regional supply, shortage mitigation, nuclear-pharmacy contracting, and markets with limited PET access.
• Excipient patents can be valuable only when tied to measurable improvements in stability, radiochemical purity, waste reduction, or workflow performance.

FAQs

Is gallium citrate Ga-67 still commercially relevant?

Yes, but primarily as a niche diagnostic agent. Its use is concentrated in selected infection, inflammation, oncology, and fever-of-unknown-origin applications.

What is the most important excipient in a Ga-67 formulation?

Citrate is the key excipient because it affects gallium complexation, solution stability, hydrolysis, and radiochemical purity.

Can a new company patent a gallium citrate Ga-67 product?

It is unlikely to obtain a strong broad patent on gallium citrate itself. Narrow patents may be available for defined formulation ranges, containers, radiolysis controls, or manufacturing processes with demonstrated technical advantages.

Is gallium citrate Ga-67 interchangeable with gallium-68 products?

No. Gallium-67 and gallium-68 differ in radionuclide properties, imaging modality, half-life, production method, and clinical workflow. They are not interchangeable products.

What is the main commercial risk for a Ga-67 manufacturer?

The principal risk is supply-chain and manufacturing reliability, including isotope availability, sterile production, release testing, transportation, and competition from FDG PET and newer targeted radiopharmaceuticals.

References

1. U.S. Food and Drug Administration. (n.d.-a). Gallium citrate Ga-67 injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs database. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.-c). Drug shortages database. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/

4. International Atomic Energy Agency. (2018). Radiopharmaceutical production and quality control. IAEA.

5. Society of Nuclear Medicine and Molecular Imaging. (n.d.). Appropriate use and clinical information for gallium imaging. SNMMI.